688621 阳光诺和
已收盘 07-31 15:00:01
资讯
新帖
简况
每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局
证券之星 · 08-02 02:44
每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局
阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”
证券之星 · 08-01 03:38
阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”
阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权
智通财经 · 07-28
阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权
阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书
智通财经 · 07-28
阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书
阳光诺和：子公司STC009注射液获临床试验批准
格隆汇 · 07-28
阳光诺和：子公司STC009注射液获临床试验批准
7月27日阳光诺和涨6.45%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 07-27
7月27日阳光诺和涨6.45%，融通健康产业灵活配置混合A/B基金重仓该股
每周股票复盘：阳光诺和（688621）2026年临时股东会审议通过发行股票议案
证券之星 · 07-26
每周股票复盘：阳光诺和（688621）2026年临时股东会审议通过发行股票议案
阳光诺和（688621）披露2026年第一次临时股东会决议公告，7月20日股价下跌1.22%
证券之星 · 07-20
阳光诺和（688621）披露2026年第一次临时股东会决议公告，7月20日股价下跌1.22%
阳光诺和（688621）新增【工业母机】概念
证券之星 · 07-20
阳光诺和（688621）新增【工业母机】概念
每周股票复盘：阳光诺和（688621）上半年净利预亏超1497万
证券之星 · 07-19
每周股票复盘：阳光诺和（688621）上半年净利预亏超1497万
阳光诺和（688621）披露控股股东协议转让部分股份暨权益变动提示性公告，7月16日股价上涨3.57%
证券之星 · 07-16
阳光诺和（688621）披露控股股东协议转让部分股份暨权益变动提示性公告，7月16日股价上涨3.57%
阳光诺和：控股股东拟协议转让5%公司股份
格隆汇 · 07-16
阳光诺和：控股股东拟协议转让5%公司股份
7月15日阳光诺和涨14.44%，融通健康产业灵活配置混合A/B基金重仓该股
证券之星 · 07-15
7月15日阳光诺和涨14.44%，融通健康产业灵活配置混合A/B基金重仓该股
股市必读：阳光诺和（688621）预计2026年1-6月归属净利润亏损1497.18万元至2994.36万元
证券之星 · 07-15
股市必读：阳光诺和（688621）预计2026年1-6月归属净利润亏损1497.18万元至2994.36万元
阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票摊薄即期回报及填补回报措施，7月14日股价上涨3.37%
证券之星 · 07-14
阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票摊薄即期回报及填补回报措施，7月14日股价上涨3.37%
阳光诺和：预计上半年净利润同比下降111.53%到123.06%
格隆汇 · 07-14
阳光诺和：预计上半年净利润同比下降111.53%到123.06%
阳光诺和：合同生效后相关研发费用由客户承担
证券之星 · 07-09
阳光诺和：合同生效后相关研发费用由客户承担
阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作
证券之星 · 07-09
阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作
阳光诺和：募集资金用于小核酸实验室和产能建设
证券之星 · 07-09
阳光诺和：募集资金用于小核酸实验室和产能建设
阳光诺和：公司多肽合成以化学合成技术为主
证券之星 · 07-09
阳光诺和：公司多肽合成以化学合成技术为主
加载更多
公司概况
公司名称：
北京阳光诺和药物研究股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-21
主营业务：
北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。
发行价格：
26.89
{"stockData":{"symbol":"688621","market":"SH","secType":"STK","nameCN":"阳光诺和","latestPrice":57.15,"timestamp":1785481201000,"preClose":56.75,"halted":0,"volume":1510234,"delay":0,"changeRate":0.007,"floatShares":112000000,"shares":112000000,"eps":1.7404,"marketStatus":"已收盘","change":0.4,"latestTime":"07-31 15:00:01","open":57,"high":58.27,"low":56,"amount":86502100,"amplitude":0.04,"askPrice":57.17,"askSize":23,"bidPrice":57.15,"bidSize":25,"shortable":0,"etf":0,"ttmEps":1.7404,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":5,"adr":0,"adjPreClose":56.75,"symbolType":"stock_kcb","openAndCloseTimeList":[[1785461400000,1785468600000],[1785474000000,1785481200000]],"highLimit":62.43,"lowLimit":51.08,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":112000000,"isCdr":false,"pbRate":5.11,"roa":"--","peRate":32.837279,"roe":"1.67%","epsLYR":1.86,"committee":-0.663158,"marketValue":6401000000,"turnoverRate":0.0135,"status":0,"afterMarket":{"amount":0,"volume":0,"close":57.15,"buyVolume":0,"sellVolume":700,"time":1785483237746,"indexStatus":"已收盘 07-31 15:30:00","preClose":56.75},"floatMarketCap":6401000000},"requestUrl":"/m/hq/s/688621/","defaultTab":"news","newsList":[{"id":"2656316026","title":"每周股票复盘：阳光诺和（688621）拟投1000万元加码纳米药物布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2656316026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656316026?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:44","pubTimestamp":1785609851,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，阳光诺和报收于57.15元，较上周的55.22元上涨3.5%。本周，阳光诺和7月28日盘中最高价报59.59元。本周关注点公司公告汇总：阳光诺和以1000万元增资上海弼领生物，持股比例升至2.2671%。公司公告汇总北京阳光诺和药物研究股份有限公司以自有资金1,000.00万元受让杭州交子茶业有限公司持有的上海弼领生物技术有限公司4.0865万元注册资本，对应持股比例由2.0435%增至2.2671%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656939623","title":"阳光诺和获得发明专利授权：“鲁拉西酮冻干口崩片及其制备方法与应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2656939623","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2656939623?lang=zh_cn&edition=full","pubTime":"2026-08-01 03:38","pubTimestamp":1785526705,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示阳光诺和新获得一项发明专利授权，专利名为“鲁拉西酮冻干口崩片及其制备方法与应用”，专利申请号为CN202111180979.1，授权日为2026年7月31日。今年以来阳光诺和新获得专利授权4个，较去年同期减少了33.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080100003600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654002197","title":"阳光诺和(688621.SH)拟1000万元受让弼领生物部分股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654002197","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654002197?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:48","pubTimestamp":1785242916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和 发布公告，为推进在新型纳米偶联药物和精准纳米递送领域的整体战略布局，公司拟以现金1000万元受让杭州交子茶业有限公司持有的上海弼领生物技术有限公司注册资本4.0865万元。本次股权转让前公司持有弼领生物2.0435%的股权，转让完成后将持有弼领生物2.2671%的股权。弼领生物已提交十余项发明专利，其中多项已在中、美、欧、日等地获权;多个候选药物正加速推进临床，未来将持续刷新治疗标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654026690","title":"阳光诺和(688621.SH)：STC009注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654026690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654026690?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:45","pubTimestamp":1785242733,"startTime":"0","endTime":"0","summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司(简称“诺和晟泰”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目STC009注射液的临床试验申请获得批准。STC009注射液拟申报适应症为继发性甲状旁腺功能亢进症(SHPT)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688621","BMED","PSYK","IBBJ","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001802","title":"阳光诺和：子公司STC009注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001802","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654001802?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:45","pubTimestamp":1785239124,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013956","title":"7月27日阳光诺和涨6.45%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013956?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:42","pubTimestamp":1785141778,"startTime":"0","endTime":"0","summary":"证券之星消息，7月27日阳光诺和涨6.45%，收盘报58.78元，换手率3.37%，成交量3.77万手，成交额2.15亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700020994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654057827","title":"每周股票复盘：阳光诺和（688621）2026年临时股东会审议通过发行股票议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2654057827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654057827?lang=zh_cn&edition=full","pubTime":"2026-07-26 02:14","pubTimestamp":1785003253,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，阳光诺和报收于55.22元，较上周的57.58元下跌4.1%。北京阳光诺和药物研究股份有限公司于2026年7月20日召开2026年第一次临时股东会，会议由董事会召集，董事长利虔先生主持，采用现场与网络投票结合方式召开，表决程序符合法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652211701","title":"阳光诺和（688621）披露2026年第一次临时股东会决议公告，7月20日股价下跌1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652211701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652211701?lang=zh_cn&edition=full","pubTime":"2026-07-20 22:38","pubTimestamp":1784558294,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘，阳光诺和报收于56.88元，较前一交易日下跌1.22%，最新总市值为63.71亿元。该股当日开盘57.82元，最高58.68元，最低54.72元，成交额达2.62亿元，换手率为4.14%。近日，阳光诺和披露《2026年第一次临时股东会决议公告》。公告显示，公司于2026年7月20日召开2026年第一次临时股东会，会议由董事会召集，董事长利虔先生主持，采用现场与网络投票结合方式召开。出席会议股东所持表决权占公司总表决权的37.2567%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000039887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652215830","title":"阳光诺和（688621）新增【工业母机】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2652215830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652215830?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:30","pubTimestamp":1784550622,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，7月20日阳光诺和新增概念。阳光诺和主营业务：涵盖创新药开发、仿制药开发及一致性评价的综合研发服务。阳光诺和2026年一季报显示，一季度公司主营收入1.97亿元，同比下降14.62%；归母净利润2063.1万元，同比下降30.25%；扣非净利润1935.42万元，同比下降4.21%；负债率44.89%，投资收益53.65万元，财务费用316.7万元，毛利率49.34%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000036252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159667","BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652723051","title":"每周股票复盘：阳光诺和（688621）上半年净利预亏超1497万","url":"https://stock-news.laohu8.com/highlight/detail?id=2652723051","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652723051?lang=zh_cn&edition=full","pubTime":"2026-07-19 02:26","pubTimestamp":1784399169,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，阳光诺和报收于57.58元，较上周的51.61元上涨11.57%。本周，阳光诺和7月17日盘中最高价报61.75元。本周关注点来自业绩披露要点：阳光诺和预计2026年上半年净利亏损1497.18万元至2994.36万元。业绩披露要点阳光诺和发布业绩预告，预计2026年1-6月扣非后净利润亏损1497.04万元至2994.08万元。本次权益变动不导致公司控制权变更，股份转让尚需上交所合规审查及完成过户登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651144012","title":"阳光诺和（688621）披露控股股东协议转让部分股份暨权益变动提示性公告，7月16日股价上涨3.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651144012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651144012?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:13","pubTimestamp":1784211196,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，阳光诺和报收于60.07元，较前一交易日上涨3.57%，最新总市值为67.28亿元。近日，阳光诺和发布《关于控股股东、实际控制人协议转让部分公司股份暨权益变动的提示性公告》。本次转让不会导致公司控股股东、实际控制人变更，不触及要约收购。受让方承诺在标的股份过户登记完成后12个月内不减持所取得的股份。本次协议转让尚需上海证券交易所合规性确认及办理股份过户登记手续，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482554","title":"阳光诺和：控股股东拟协议转让5%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482554","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651482554?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:53","pubTimestamp":1784195636,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651045345","title":"7月15日阳光诺和涨14.44%，融通健康产业灵活配置混合A/B基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651045345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651045345?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:24","pubTimestamp":1784103875,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日阳光诺和涨14.44%，收盘报58.0元，换手率9.91%，成交量11.1万手，成交额6.31亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为融通基金的融通健康产业灵活配置混合A/B。融通健康产业灵活配置混合A/B的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651485382","title":"股市必读：阳光诺和（688621）预计2026年1-6月归属净利润亏损1497.18万元至2994.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651485382","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651485382?lang=zh_cn&edition=full","pubTime":"2026-07-15 02:28","pubTimestamp":1784053690,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩预告阳光诺和预计2026年1–6月归属净利润为–1497.18万元至–2994.36万元；扣非后净利润为–1497.04万元至–2994.08万元。公司公告汇总自愿披露2026年半年度业绩预告的公告北京阳光诺和药物研究股份有限公司预计2026年半年度实现归属于母公司所有者的净利润为–1,497.18万元至–2,994.36万元，同比减少111.53%到123.06%；扣除非经常性损益后的净利润为–1,497.04万元至–2,994.08万元，同比下降112.51%到125.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500002748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410421","title":"阳光诺和（688621）披露2026年度以简易程序向特定对象发行股票摊薄即期回报及填补回报措施，7月14日股价上涨3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410421","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651410421?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:35","pubTimestamp":1784039713,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，阳光诺和报收于50.68元，较前一交易日上涨3.37%，最新总市值为56.76亿元。近日，北京阳光诺和药物研究股份有限公司披露《2026年第一次临时股东会会议资料》，其中包含关于2026年度以简易程序向特定对象发行股票摊薄即期回报及填补回报措施的议案。公告显示，公司就本次发行对即期回报的影响进行了测算，并提出填补回报的具体措施，相关主体出具了承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651817174","title":"阳光诺和：预计上半年净利润同比下降111.53%到123.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651817174","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651817174?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:06","pubTimestamp":1784023591,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944171","title":"阳光诺和：合同生效后相关研发费用由客户承担","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944171?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582631,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司自研项目BD后研发费用是否由客户承担，如STC007等项目研发费用今后不会在报表中体现？阳光诺和回复：合同生效后，后续临床试验、注册申报及商业化阶段的主要研发工作由客户负责组织实施，相关研发费用由客户承担。感谢您对公司的关注与支持。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944197","title":"阳光诺和：公司正基于管线进展有序推进国内外合作洽谈相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944197","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944197?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582626,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司进行中的BD有？，在谈中的创新药BD有？有什么创新药成果？阳光诺和回复：公司正基于管线进展有序推进国内外合作洽谈相关工作，若有达成实质性合作，将根据《上海证券交易所股票上市规则》等相关要求及时披露。后续公司将持续通过对外授权、联合开发等多元化模式，最大化管线价值，具体合作动态请以公司公告为准。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944144","title":"阳光诺和：募集资金用于小核酸实验室和产能建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944144?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582625,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：2025 年公司新签订单突破 20 亿，现有实验室产能能否匹配未来 2 年订单交付？是否启动新研发基地扩建、新增临床分析实验室规划？公司持续关注产能建设与订单交付、自主研发的匹配。近期，公司公告以简易程序向特定对象发行股票预案，募集资金用于小核酸实验室和产能建设。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688621","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650944108","title":"阳光诺和：公司多肽合成以化学合成技术为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2650944108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650944108?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:37","pubTimestamp":1783582623,"startTime":"0","endTime":"0","summary":"证券之星消息，阳光诺和(688621)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问：多肽原料药合成生物学酶法工艺是否完成内部验证？未来能否对外提供合成生物中间体研发服务，该技术能否大幅降低公司多肽类项目研发成本、提升整体毛利率？有无相关产学研合作落地？阳光诺和回复：尊敬的投资者，您好！公司多肽合成以化学合成技术为主。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900022551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688621"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1785706000753,"stockEarnings":[{"period":"1week","weight":0.035},{"period":"1month","weight":0.0137},{"period":"3month","weight":-0.0056},{"period":"6month","weight":-0.1165},{"period":"1year","weight":0.053},{"period":"ytd","weight":-0.0771}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0681},{"period":"3month","weight":-0.0681},{"period":"6month","weight":-0.0694},{"period":"1year","weight":0.0725},{"period":"ytd","weight":-0.0344}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京阳光诺和药物研究股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"7988人(较上一季度增加11.58%)","perCapita":"14021股","listingDate":"2021-06-21","address":"北京市昌平区科技园区双营西路79号院7号楼一层","registeredCapital":"11200万元","survey":" 北京阳光诺和药物研究股份有限公司的主营业务是为国内医药企业和科研机构提供全过程的一站式药物研发服务。公司的主要产品是仿制药药学研究服务、临床试验及生物分析服务、创新药、改良型新药研发服务、知识产权授权、权益分成。","listedPrice":26.89},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阳光诺和,688621,阳光诺和股票,阳光诺和股票老虎,阳光诺和股票老虎国际,阳光诺和行情,阳光诺和股票行情,阳光诺和股价,阳光诺和股市,阳光诺和股票价格,阳光诺和股票交易,阳光诺和股票购买,阳光诺和股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阳光诺和(688621)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阳光诺和(688621)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}